vs
爱德华生命科学（EW）与美泰（MAT）财务数据对比。点击上方公司名可切换其他公司
爱德华生命科学的季度营收约是美泰的1.9倍（$1.6B vs $862.2M），爱德华生命科学净利率更高（23.1% vs 7.1%，领先16.0%），爱德华生命科学同比增速更快（16.7% vs 4.3%），过去两年爱德华生命科学的营收复合增速更高（9.7% vs -10.6%）
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
EW vs MAT — 直观对比
营收规模更大
EW
是对方的1.9倍
$862.2M
营收增速更快
EW
高出12.4%
4.3%
净利率更高
EW
高出16.0%
7.1%
两年增速更快
EW
近两年复合增速
-10.6%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $862.2M |
| 净利润 | $380.7M | $61.0M |
| 毛利率 | 78.0% | 44.9% |
| 营业利润率 | 1.8% | — |
| 净利率 | 23.1% | 7.1% |
| 营收同比 | 16.7% | 4.3% |
| 净利润同比 | 6.8% | 251.4% |
| 每股收益（稀释后） | $0.66 | $0.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWMAT
| Q1 26 | $1.6B | $862.2M | ||
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.6B | $1.7B | ||
| Q2 25 | $1.5B | $1.0B | ||
| Q1 25 | $1.4B | $826.6M | ||
| Q4 24 | $1.4B | $1.6B | ||
| Q3 24 | $1.4B | $1.8B | ||
| Q2 24 | $1.4B | $1.1B |
净利润EWMAT
| Q1 26 | $380.7M | $61.0M | ||
| Q4 25 | $91.2M | $106.2M | ||
| Q3 25 | $291.1M | $278.4M | ||
| Q2 25 | $333.2M | $53.4M | ||
| Q1 25 | $358.0M | $-40.3M | ||
| Q4 24 | $385.6M | $140.9M | ||
| Q3 24 | $3.1B | $372.4M | ||
| Q2 24 | $366.3M | $56.9M |
毛利率EWMAT
| Q1 26 | 78.0% | 44.9% | ||
| Q4 25 | 78.1% | 45.9% | ||
| Q3 25 | 77.8% | 50.0% | ||
| Q2 25 | 77.5% | 50.9% | ||
| Q1 25 | 78.7% | 49.4% | ||
| Q4 24 | 78.9% | 50.7% | ||
| Q3 24 | 80.6% | 53.1% | ||
| Q2 24 | 79.9% | 49.2% |
营业利润率EWMAT
| Q1 26 | 1.8% | — | ||
| Q4 25 | 9.6% | 8.0% | ||
| Q3 25 | 19.8% | 21.9% | ||
| Q2 25 | 26.8% | 7.7% | ||
| Q1 25 | 27.9% | -6.4% | ||
| Q4 24 | 22.6% | 9.6% | ||
| Q3 24 | 25.9% | 26.5% | ||
| Q2 24 | 26.8% | 7.7% |
净利率EWMAT
| Q1 26 | 23.1% | 7.1% | ||
| Q4 25 | 5.8% | 6.0% | ||
| Q3 25 | 18.7% | 16.0% | ||
| Q2 25 | 21.7% | 5.2% | ||
| Q1 25 | 25.3% | -4.9% | ||
| Q4 24 | 27.8% | 8.6% | ||
| Q3 24 | 226.7% | 20.2% | ||
| Q2 24 | 26.7% | 5.3% |
每股收益（稀释后）EWMAT
| Q1 26 | $0.66 | $0.20 | ||
| Q4 25 | $0.16 | $0.32 | ||
| Q3 25 | $0.50 | $0.88 | ||
| Q2 25 | $0.56 | $0.16 | ||
| Q1 25 | $0.61 | $-0.12 | ||
| Q4 24 | $0.65 | $0.40 | ||
| Q3 24 | $5.13 | $1.09 | ||
| Q2 24 | $0.61 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $866.0M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | — | $2.1B |
| 总资产 | — | $6.3B |
| 负债/权益比越低杠杆越低 | — | 1.11× |
8季度趋势，按日历期对齐
现金及短期投资EWMAT
| Q1 26 | — | $866.0M | ||
| Q4 25 | $4.2B | $1.2B | ||
| Q3 25 | $3.8B | $691.9M | ||
| Q2 25 | $4.1B | $870.5M | ||
| Q1 25 | $3.9B | $1.2B | ||
| Q4 24 | $4.0B | $1.4B | ||
| Q3 24 | $4.4B | $723.5M | ||
| Q2 24 | $2.0B | $722.4M |
总债务EWMAT
| Q1 26 | — | $2.3B | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.3B |
股东权益EWMAT
| Q1 26 | — | $2.1B | ||
| Q4 25 | $10.3B | $2.2B | ||
| Q3 25 | $10.2B | $2.3B | ||
| Q2 25 | $10.5B | $2.2B | ||
| Q1 25 | $10.1B | $2.1B | ||
| Q4 24 | $10.0B | $2.3B | ||
| Q3 24 | $9.5B | $2.3B | ||
| Q2 24 | $7.4B | $2.0B |
总资产EWMAT
| Q1 26 | — | $6.3B | ||
| Q4 25 | $13.7B | $6.6B | ||
| Q3 25 | $13.3B | $6.6B | ||
| Q2 25 | $13.5B | $6.2B | ||
| Q1 25 | $13.0B | $6.2B | ||
| Q4 24 | $13.1B | $6.5B | ||
| Q3 24 | $13.0B | $6.5B | ||
| Q2 24 | $10.1B | $5.9B |
负债/权益比EWMAT
| Q1 26 | — | 1.11× | ||
| Q4 25 | — | 1.04× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.08× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.03× | ||
| Q3 24 | — | 1.01× | ||
| Q2 24 | — | 1.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | — | $-88.1M |
| 自由现金流率自由现金流/营收 | — | -10.2% |
| 资本支出强度资本支出/营收 | — | 7.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流EWMAT
| Q1 26 | — | — | ||
| Q4 25 | $450.9M | $796.6M | ||
| Q3 25 | $573.7M | $72.0M | ||
| Q2 25 | $290.2M | $-300.1M | ||
| Q1 25 | $280.4M | $24.8M | ||
| Q4 24 | $-127.5M | $862.1M | ||
| Q3 24 | $351.8M | $155.8M | ||
| Q2 24 | $371.5M | $-252.9M |
自由现金流EWMAT
| Q1 26 | — | $-88.1M | ||
| Q4 25 | $353.5M | — | ||
| Q3 25 | $516.2M | — | ||
| Q2 25 | $240.9M | — | ||
| Q1 25 | $224.4M | — | ||
| Q4 24 | $-177.3M | — | ||
| Q3 24 | $299.9M | — | ||
| Q2 24 | $286.1M | — |
自由现金流率EWMAT
| Q1 26 | — | -10.2% | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 33.2% | — | ||
| Q2 25 | 15.7% | — | ||
| Q1 25 | 15.9% | — | ||
| Q4 24 | -12.8% | — | ||
| Q3 24 | 22.1% | — | ||
| Q2 24 | 20.9% | — |
资本支出强度EWMAT
| Q1 26 | — | 7.6% | ||
| Q4 25 | 6.2% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 3.6% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 6.2% | — |
现金转化率EWMAT
| Q1 26 | — | — | ||
| Q4 25 | 4.94× | 7.50× | ||
| Q3 25 | 1.97× | 0.26× | ||
| Q2 25 | 0.87× | -5.62× | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | -0.33× | 6.12× | ||
| Q3 24 | 0.11× | 0.42× | ||
| Q2 24 | 1.01× | -4.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
